

Solos Endoscopy, Inc. Reports Sales and Gross Profits Increase for The First Quarter Ended March 31, 2019

WESTPORT, May 16, 2019 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) a provider of quality medical devices to hospitals and clinics across the country, has announced that the company realized significant growth in first quarter sales and profits compared to the same period in 2018.

Sales for the first quarter ended March 31, 2019 were \$63K, a 35% increase compared to \$46K for the same period in 2018. Total sales growth for the first quarter showed 60% contribution from the MammoView products, and an approximately 40% from core Solos products. Gross Profits for the first quarter were up 62% to \$42K from the same period last year. After the impact of derivative liability losses and other costs primarily related to business operations, adjusted net income was \$(172K), a nearly \$500K improvement from the first quarter of 2018.

The company's Chief Executive Officer, Dom Gatto stated, "We are pleased to be off to a good start in 2019 and look forward to maintaining our sales growth throughout 2019 as we focus on the breast healthcare marketplace with our MammoView Breast Endoscopy products. We enter the second quarter of 2019 focused on the further strengthening of our company for the longer term, by driving strong and sustainable sales growth and improving our operating results. We plan to support these objectives with a targeted strategy for procuring essential growth capital and recruiting key personnel, while increasing our development efforts within the breast healthcare marketplace. We believe our focus in this growing market area will create significant value for our shareholders."

About Solos Endoscopy, Inc.:

Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcm Markets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9700